202 related articles for article (PubMed ID: 29577674)
1. A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTKorea.
Shin J; Koh Y; Yoon SH; Cho JY; Kim DY; Lee KH; Kim HJ; Ahn JS; Kim YK; Park J; Sohn SK; Moon JH; Lee YJ; Yoon S; Lee JO; Cheong JW; Kim KH; Kim SH; Kim HG; Kim H; Nam SH; Do YR; Park SG; Park SK; Bae SH; Song HH; Shin DY; Oh D; Kim MK; Jung CW; Park S; Kim I
Cancer Med; 2018 May; 7(5):1814-1823. PubMed ID: 29577674
[TBL] [Abstract][Full Text] [Related]
2. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
[TBL] [Abstract][Full Text] [Related]
3. Frontline nilotinib treatment in Turkish patients with Philadelphia chromosome-positive chronic Myeloid Leukemia in chronic phase: updated results with 2 years of follow-up.
Saydam G; Haznedaroglu IC; Kaynar L; Yavuz AS; Ali R; Guvenc B; Akay OM; Baslar Z; Ozbek U; Sonmez M; Aydin D; Pehlivan M; Undar B; Dagdas S; Ayyildiz O; Akin G; Dag IM; Ilhan O
Hematology; 2018 Dec; 23(10):771-777. PubMed ID: 29996726
[TBL] [Abstract][Full Text] [Related]
4. Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
Nicolini FE; Turkina A; Shen ZX; Gallagher N; Jootar S; Powell BL; De Souza C; Zheng M; Szczudlo T; le Coutre P
Cancer; 2012 Jan; 118(1):118-26. PubMed ID: 21732337
[TBL] [Abstract][Full Text] [Related]
5. Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients.
Zhou L; Meng F; Yin O; Wang J; Wang Y; Wei Y; Hu P; Shen Z
Clin Ther; 2009 Jul; 31(7):1568-75. PubMed ID: 19695406
[TBL] [Abstract][Full Text] [Related]
6. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
Kantarjian HM; Giles F; Gattermann N; Bhalla K; Alimena G; Palandri F; Ossenkoppele GJ; Nicolini FE; O'Brien SG; Litzow M; Bhatia R; Cervantes F; Haque A; Shou Y; Resta DJ; Weitzman A; Hochhaus A; le Coutre P
Blood; 2007 Nov; 110(10):3540-6. PubMed ID: 17715389
[TBL] [Abstract][Full Text] [Related]
7. Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis.
Nicolini FE; Masszi T; Shen Z; Gallagher NJ; Jootar S; Powell BL; Dorlhiac-Llacer PE; Zheng M; Szczudlo T; Turkina A
Leuk Lymphoma; 2012 May; 53(5):907-14. PubMed ID: 22023530
[TBL] [Abstract][Full Text] [Related]
8. Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.
Saydam G; Haznedaroglu IC; Kaynar L; Yavuz AS; Ali R; Guvenc B; Akay OM; Baslar Z; Ozbek U; Sonmez M; Aydin D; Pehlivan M; Undar B; Dagdas S; Ayyildiz O; Akkaynak DZ; Dag IM; Ilhan O
Expert Opin Pharmacother; 2016 Oct; 17(14):1851-8. PubMed ID: 27501474
[TBL] [Abstract][Full Text] [Related]
9. Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia.
Giles FJ; Yin OQ; Sallas WM; le Coutre PD; Woodman RC; Ottmann OG; Baccarani M; Kantarjian HM
Eur J Clin Pharmacol; 2013 Apr; 69(4):813-23. PubMed ID: 23052406
[TBL] [Abstract][Full Text] [Related]
10. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
Saglio G; Kim DW; Issaragrisil S; le Coutre P; Etienne G; Lobo C; Pasquini R; Clark RE; Hochhaus A; Hughes TP; Gallagher N; Hoenekopp A; Dong M; Haque A; Larson RA; Kantarjian HM;
N Engl J Med; 2010 Jun; 362(24):2251-9. PubMed ID: 20525993
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia.
Hijiya N; Maschan A; Rizzari C; Shimada H; Dufour C; Goto H; Kang HJ; Guinipero T; Karakas Z; Bautista F; Ducassou S; Yoo KH; Zwaan CM; Millot F; Aimone P; Allepuz A; Quenet S; Hourcade-Potelleret F; Hertle S; Sosothikul D
Blood; 2019 Dec; 134(23):2036-2045. PubMed ID: 31511239
[TBL] [Abstract][Full Text] [Related]
12. Nilotinib: in the first-line treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase.
Garnock-Jones KP
Drugs; 2011 Aug; 71(12):1579-90. PubMed ID: 21861543
[TBL] [Abstract][Full Text] [Related]
13. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results.
le Coutre PD; Giles FJ; Hochhaus A; Apperley JF; Ossenkoppele GJ; Blakesley R; Shou Y; Gallagher NJ; Baccarani M; Cortes J; Kantarjian HM
Leukemia; 2012 Jun; 26(6):1189-94. PubMed ID: 22076466
[TBL] [Abstract][Full Text] [Related]
14. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
Deremer DL; Ustun C; Natarajan K
Clin Ther; 2008 Nov; 30(11):1956-75. PubMed ID: 19108785
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.
Hiwase D; Tan P; D'Rozario J; Taper J; Powell A; Irving I; Wright M; Branford S; Yeung DT; Anderson L; Gervasio O; Levetan C; Roberts W; Solterbeck A; Traficante R; Hughes T
Leuk Res; 2018 Apr; 67():109-115. PubMed ID: 29494928
[TBL] [Abstract][Full Text] [Related]
16. NOVEL-1st: an observational study to assess the safety and efficacy of nilotinib in newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase in Taiwan.
Hwang WL; Chen TC; Lin HY; Chang MC; Hsiao PC; Bai LY; Kuo CY; Chen YC; Liu TC; Gau JP; Wang PN; Hwang WS; Kuo MC; Liu CY; Liu YC; Ma MC; Su NW; Wang CC; Wu YY; Yao M; Yeh SP; Cheng HW; Lee YM; Ku FC; Tang JL
Int J Hematol; 2022 May; 115(5):704-712. PubMed ID: 35212915
[TBL] [Abstract][Full Text] [Related]
17. Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial.
Cortes JE; De Souza CA; Ayala M; Lopez JL; Bullorsky E; Shah S; Huang X; Babu KG; Abdulkadyrov K; de Oliveira JSR; Shen ZX; Sacha T; Bendit I; Liang Z; Owugah T; Szczudlo T; Khanna S; Fellague-Chebra R; le Coutre PD
Lancet Haematol; 2016 Dec; 3(12):e581-e591. PubMed ID: 27890073
[TBL] [Abstract][Full Text] [Related]
18. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.
Larson RA; Hochhaus A; Hughes TP; Clark RE; Etienne G; Kim DW; Flinn IW; Kurokawa M; Moiraghi B; Yu R; Blakesley RE; Gallagher NJ; Saglio G; Kantarjian HM
Leukemia; 2012 Oct; 26(10):2197-203. PubMed ID: 22699418
[TBL] [Abstract][Full Text] [Related]
19. Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial.
Nakamae H; Fukuda T; Nakaseko C; Kanda Y; Ohmine K; Ono T; Matsumura I; Matsuda A; Aoki M; Ito K; Shibayama H
Int J Hematol; 2018 Mar; 107(3):327-336. PubMed ID: 29076005
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of switching to nilotinib in patients with CML-CP in major molecular response to imatinib: results of a multicenter phase II trial (NILSw trial).
Ishikawa J; Matsumura I; Kawaguchi T; Kuroda J; Nakamae H; Miyamoto T; Matsuoka KI; Shibayama H; Hino M; Hirase C; Kamimura T; Shimose T; Akashi K; Kanakura Y
Int J Hematol; 2018 May; 107(5):535-540. PubMed ID: 29362980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
